SCHEMBL2018995

SCHEMBL2018995

COC(=O)C[C@@H](N)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 4/20 0.58
SLC7A5 Q01650 2/20 0.50
GRIK1 P39086 9/20 0.48
GRIK2 Q13002 5/20 0.48
GRM1 Q13255 1/20 0.46
GRM2 Q14416 1/20 0.46
GRIA4 P48058 3/20 0.45
GRIK3 Q13003 3/20 0.45
GRIK5 Q16478 3/20 0.45
SLC1A3 P43003 4/20 0.45
SLC1A2 P43004 4/20 0.45
GRIA2 P42262 2/20 0.44
GRIA1 P42261 1/20 0.44
GFPT1 Q06210 1/20 0.43
PTGS1 P23219 1/20 0.42
SLC7A11 Q9UPY5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536243 1.00 SLC1A1 (0.58) SLC1A1SLC7A5GRIK1GRIK2GRM1
SCHEMBL151676 1.00 SLC1A1 (0.58) SLC1A1SLC7A5GRIK1GRIK2GRM1
Hydrochloric Acid SCHEMBL6506409 0.98 SLC1A1 (0.56) SLC1A1SLC7A5GRIK1GRIK2GRM1
SCHEMBL2238405 0.98 SLC1A1 (0.56) SLC1A1SLC7A5GRIK1GRIK2GRM1
Hydrochloric Acid SCHEMBL933300 0.98 SLC1A1 (0.56) SLC1A1SLC7A5GRIK1GRIK2GRM1
Hydrochloric Acid SCHEMBL23851398 0.98 SLC1A1 (0.56) SLC1A1SLC7A5GRIK1GRIK2GRM1
Hydrochloric Acid SCHEMBL25212271 0.96 SLC1A1 (0.55) SLC1A1SLC7A5GRIK1GRIK2GRM1
SCHEMBL9449386 0.86 SLC1A1 (0.54) SLC1A1SLC7A5GRIK1GRIK2GRM1
SCHEMBL7359265 0.86 SLC1A1 (0.54) SLC1A1SLC7A5GRIK1GRIK2GRM1
SCHEMBL5050477 0.85 SLC1A1 (0.53) SLC1A1SLC7A5GRIK1GRIK2GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113999251-A Synthetic method of aspoxicillin sodium 海南海灵化学制药有限公司 2022-02-01 CN claimed
CN-116262736-B Novel oxo-pyridine compound and preparation method and application thereof 成都施贝康生物医药科技有限公司 2025-05-13 CN disclosed
CN-117897388-A BTK protein degradation agent 广州麓鹏制药有限公司 2024-04-16 CN disclosed
US-20240058457-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. (US) 2024-02-22 US disclosed
EP-4263552-A1 BTK DEGRADER Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) 2023-10-25 EP disclosed
US-11780853-B2 Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors PFIZER INC. (US) 2023-10-10 US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
CN-116262736-A Novel oxo-pyridine compound and preparation method and application thereof 成都施贝康生物医药科技有限公司 2023-06-16 CN disclosed
US-20230127805-A1 PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF ROTTAPHARM BIOTECH S.R.L. (IT) 2023-04-27 US disclosed
US-20230127805-A1 PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF ROTTAPHARM BIOTECH S.R.L. (IT) 2023-04-27 US disclosed
CN-102958932-A 5-HT receptor modulators and methods of use thereof ABBVI INC 2013-03-06 CN disclosed
US-20120202809-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PFIZER INC. 2012-08-09 US disclosed
US-20120202809-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PFIZER INC. 2012-08-09 US disclosed
US-8183255-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER, INC. (US) 2012-05-22 US disclosed
US-8183255-B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors PFIZER, INC. (US) 2012-05-22 US disclosed
US-20110130382-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-06-02 US disclosed
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-05-27 US disclosed
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-05-27 US disclosed
WO-2008096260-A1 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS PFIZER INC. (US) 2008-08-14 WO disclosed
US-7253194-B2 Compounds and inhibitors of phospholipases THE UNIVERSITY OF QUEENSLAND (AU) 2007-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780853-B2 Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors PRKCB, PRKCA, PRKCQ SLC1A1 2736/4885SLC7A5 3872/4885GRIK1 442/4885
US-20230127805-A1 PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF BACH1, ADH1C, ADH1A SLC1A1 3233/4885SLC7A5 3475/4885GRIK1 2302/4885
US-20110130382-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR4, HTR1A, HTR1D SLC1A1 408/4885SLC7A5 3046/4885GRIK1 133/4885
US-20240058457-A1 BTK DEGRADER BTK, LYN, SYK SLC1A1 4855/4885SLC7A5 4789/4885GRIK1 3418/4885
US-20100130501-A1 NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES DPP3, IAPP, GPR119 SLC1A1 668/4885SLC7A5 1420/4885GRIK1 2212/4885
US-20120202809-A1 NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS PRKCB, PRKCA, PRKCE SLC1A1 2244/4885SLC7A5 2898/4885GRIK1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.